Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer
Status:
Recruiting
Trial end date:
2024-10-15
Target enrollment:
Participant gender:
Summary
This is a prospective Single-arm Study to Investigate the Efficacy and Safety of Neoadjuvant
treatment with trastuzumab and pyrotinib plus palbociclib and fulvestrant in HER2-positive,
ER-positive breast cancer.